EP2663331A4 - Nouvelles utilisations - Google Patents

Nouvelles utilisations

Info

Publication number
EP2663331A4
EP2663331A4 EP12734212.9A EP12734212A EP2663331A4 EP 2663331 A4 EP2663331 A4 EP 2663331A4 EP 12734212 A EP12734212 A EP 12734212A EP 2663331 A4 EP2663331 A4 EP 2663331A4
Authority
EP
European Patent Office
Prior art keywords
new uses
new
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12734212.9A
Other languages
German (de)
English (en)
Other versions
EP2663331A1 (fr
Inventor
Frederick J Derosier
Immanuel Freedman
Ole Graff
Richard A Grove
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Glaxosmithkline Intellectual Property Management Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd, Glaxosmithkline Intellectual Property Management Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of EP2663331A1 publication Critical patent/EP2663331A1/fr
Publication of EP2663331A4 publication Critical patent/EP2663331A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP12734212.9A 2011-01-10 2012-01-10 Nouvelles utilisations Withdrawn EP2663331A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161431194P 2011-01-10 2011-01-10
PCT/US2012/020729 WO2012096924A1 (fr) 2011-01-10 2012-01-10 Nouvelles utilisations

Publications (2)

Publication Number Publication Date
EP2663331A1 EP2663331A1 (fr) 2013-11-20
EP2663331A4 true EP2663331A4 (fr) 2015-07-15

Family

ID=46507398

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12734212.9A Withdrawn EP2663331A4 (fr) 2011-01-10 2012-01-10 Nouvelles utilisations

Country Status (4)

Country Link
US (2) US20130315901A1 (fr)
EP (1) EP2663331A4 (fr)
JP (1) JP2014506258A (fr)
WO (1) WO2012096924A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015162504A1 (fr) 2014-04-23 2015-10-29 Novartis Ag Nouveau dosage et nouvelles utilisations de l'ofatumumab
GB201419084D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-PD-1 antibodies
AU2016282334B2 (en) 2015-06-24 2022-07-21 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
MX2018003822A (es) 2015-10-02 2018-06-22 Hoffmann La Roche Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso.
JP2018529747A (ja) * 2015-10-06 2018-10-11 ジェネンテック， インコーポレイテッド 多発性硬化症を治療するための方法
US11248057B2 (en) * 2016-03-07 2022-02-15 Vib Vzw CD20 binding single domain antibodies
EP4252847A3 (fr) * 2016-08-15 2023-11-15 Novartis AG Régimes et procédés de traitement de la sclérose en plaques à l'aide d'ofatumumab
AU2018379306A1 (en) * 2017-12-05 2020-06-25 Mabion Sa Combination therapy of multiple sclerosis comprising a CD20 ligand
CN113358881B (zh) * 2021-08-10 2021-11-30 首都医科大学附属北京天坛医院 用于nmosd预测或复发监测的生物标志物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033587A2 (fr) * 2008-09-16 2010-03-25 Genentech, Inc. Procédés permettant le traitement de la sclérose en plaques progressive

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100944575B1 (ko) * 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
US20060188495A1 (en) * 2005-01-13 2006-08-24 Genentech, Inc. Treatment method
AR077718A1 (es) * 2008-07-15 2011-09-21 Genentech Inc Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica
CN102159243B (zh) * 2008-07-21 2015-08-19 免疫医疗公司 用于改良的治疗特征的抗体的结构变体

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010033587A2 (fr) * 2008-09-16 2010-03-25 Genentech, Inc. Procédés permettant le traitement de la sclérose en plaques progressive

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "NCT00686868: Clinical Phase I/IIA Study of Subcutaneously Administration of Ofatumumab in Rheumatoid Arthritis Patients on Stable Dose Methotrexate", 31 March 2010 (2010-03-31), XP055190949, Retrieved from the Internet <URL:https://clinicaltrials.gov/archive/NCT00686868/2010_03_31> [retrieved on 20150521] *
CREE B A C ET AL: "AN OPEN LABEL STUDY OF THE EFFECTS OF RITUXIMAB IN NEUROMYELITIS OPTICA", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 64, no. 7, 12 April 2005 (2005-04-12), pages 1270 - 1272, XP009071970, ISSN: 0028-3878 *
CREE BRUCE ET AL: "Tolerability and effects of Rituximab (anti-CD20 antibody) in neuromyelitis optica (NMO) and rapidly worsening multiple sclerosis (MS)", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 62, no. 7, Suppl. 5, 1 April 2004 (2004-04-01), pages A492, XP009080814, ISSN: 0028-3878 *
IMAMURA HISAJI ET AL: "[Trial of rituximab in three patients with neuromyelitis optica].", RINSHO SHINKEIGAKU = CLINICAL NEUROLOGY AUG 2009, vol. 49, no. 8, August 2009 (2009-08-01), pages 457 - 462, XP055191431, ISSN: 0009-918X *
JACOB ANU ET AL: "Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.", ARCHIVES OF NEUROLOGY NOV 2008, vol. 65, no. 11, November 2008 (2008-11-01), pages 1443 - 1448, XP002740003, ISSN: 1538-3687 *
MIRAVALLE AUGUSTO A ET AL: "B Cell Depletion and Safety of Low Dose Rituximab in Patients with Relapsing Multiple Sclerosis", NEUROLOGY, LIPPINCOTT WILLIAMS & WILKINS, PHILADELPHIA, US, vol. 72, no. 11, Suppl.3, 29 April 2009 (2009-04-29), pages A358, XP009184401, ISSN: 0028-3878 *
NIELSEN A SCOTT ET AL: "Maximally tolerated versus minimally effective dose: the case of rituximab in multiple sclerosis", MULTIPLE SCLEROSIS (HOUNDMILLS, BASINGSTOKE, ENGLAND) APR 2012,, vol. 18, no. 3, 9 August 2011 (2011-08-09), pages 377 - 378, XP009184408, ISSN: 1477-0970 *
PER SOELBERG SORENSEN ET AL: "Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS) - 24-week results of a phase II study", 26TH CONGRESS OF THE EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) & 15TH ANNUAL CONFERENCE OF REHABILITATION IN MS (RIMS) 13.10.2010 - 16.10.2010, 16 October 2010 (2010-10-16), XP055191485, Retrieved from the Internet <URL:http://registration.akm.ch/einsicht.php?XNABSTRACT_ID=118695&XNSPRACHE_ID=2&XNKONGRESS_ID=126&XNMASKEN_ID=900> [retrieved on 20150526] *
See also references of WO2012096924A1 *
WIM K. BLEEKER ET AL: "Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody", BRITISH JOURNAL OF HAEMATOLOGY, vol. 140, no. 3, 1 February 2008 (2008-02-01), pages 303 - 312, XP055190973, ISSN: 0007-1048, DOI: 10.1111/j.1365-2141.2007.06916.x *

Also Published As

Publication number Publication date
US20130315901A1 (en) 2013-11-28
JP2014506258A (ja) 2014-03-13
WO2012096924A1 (fr) 2012-07-19
EP2663331A1 (fr) 2013-11-20
US20160090421A1 (en) 2016-03-31

Similar Documents

Publication Publication Date Title
DK3424953T3 (en) Terapeutiske antistoffer
EP2754063A4 (fr) Extensibilité du protocole smb2
EP2723631A4 (fr) Catamaran à quatre ailes portantes
EP2776444A4 (fr) Dihydroptéridinones
AP2014007621A0 (en) 2-Thiopyrimidinones
ZA201304866B (en) Colonoscopy-preparation
DK2770906T3 (en) Applanationstonometer
GB201119167D0 (en) Novel bachteriophages
GB201101727D0 (en) Obuoy
GB201100001D0 (en) TidySqueeze2
AU5031P (en) BESYS Beschorneria yuccoides
AU4540P (en) BUNNAN Baloskion tetraphyllum
AU5026P (en) Goldstrike Agapanthus inapertus
AU5171P (en) Sunparamiho Mandevilla xamabilis
GB201113206D0 (en) Novel uses
GB201107854D0 (en) Novel 5-hydroxy-5-aryl-pyrrol-2-ones
GB201113923D0 (en) Novel combinations
GB201109229D0 (en) New uses
GB201108947D0 (en) Novel use
GB201103770D0 (en) Novel use
AP00723S1 (en) Autorickshaw
GB201101143D0 (en) Post-reference
GB201102635D0 (en) Panalock
GB201101675D0 (en) i-mc
GB201102667D0 (en) Coolbreeze

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20130730

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY MANAGEMENT L

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/395 20060101AFI20150603BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150612

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NOVARTIS AG

17Q First examination report despatched

Effective date: 20170321

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20170508